Cell MedX Corp
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System fo… Read more
Market Cap & Net Worth: Cell MedX Corp (CMXC)
Cell MedX Corp (OTCQB:CMXC) has a market capitalization of $126.33 Million ($126.33 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #24080 globally and #8358 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cell MedX Corp's stock price $0.43 by its total outstanding shares 297236000 (297.24 Million).
Cell MedX Corp Market Cap History: 2015 to 2024
Cell MedX Corp's market capitalization history from 2015 to 2024. Data shows change from $497.89 Billion to $126.33 Million (-60.03% CAGR).
Cell MedX Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cell MedX Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
285599996.20x
Cell MedX Corp's market cap is 285599996.20 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $497.89 Billion | $42.62K | -$1.03 Million | 11680864.34x | N/A |
| 2016 | $455.53 Billion | $36.56K | -$2.14 Million | 12460788.13x | N/A |
| 2017 | $514.85 Billion | $6.22K | -$1.25 Million | 82773296.86x | N/A |
| 2020 | $486.29 Billion | $95.82K | -$1.09 Million | 5074855.55x | N/A |
| 2021 | $579.01 Billion | $6.76K | -$910.84K | 85626781.59x | N/A |
| 2022 | $572.39 Billion | $6.07K | -$697.38K | 94375493.03x | N/A |
| 2023 | $788.83 Billion | $2.76K | -$495.04K | 285599996.20x | N/A |
Competitor Companies of CMXC by Market Capitalization
Companies near Cell MedX Corp in the global market cap rankings as of March 19, 2026.
Key companies related to Cell MedX Corp by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Cell MedX Corp Historical Marketcap From 2015 to 2024
Between 2015 and today, Cell MedX Corp's market cap moved from $497.89 Billion to $ 126.33 Million, with a yearly change of -60.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $126.33 Million | -99.98% |
| 2023 | $788.83 Billion | +37.81% |
| 2022 | $572.39 Billion | -1.14% |
| 2021 | $579.01 Billion | +19.07% |
| 2020 | $486.29 Billion | -0.08% |
| 2019 | $486.67 Billion | +9.80% |
| 2018 | $443.25 Billion | -13.91% |
| 2017 | $514.85 Billion | +13.02% |
| 2016 | $455.53 Billion | -8.51% |
| 2015 | $497.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 28th, 2025 the market cap of Cell MedX Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $126.33 Million USD |
| MoneyControl | $126.33 Million USD |
| MarketWatch | $126.33 Million USD |
| marketcap.company | $126.33 Million USD |
| Reuters | $126.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.